Journal of
Diabetes Nursing
Volume 12, Issue 4 (10-2024)
J Diabetes Nurs 2024, 12(4): 2535-2546 |
Back to browse issues page
Research code: IR.SBMU.RETECH.REC.1403.330
Ethics code: IR.SBMU.RETECH.REC.1403.330IR.SBMU.RETECH.REC.1403.330
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebadi A, Homaee S, Sadeghi S, Dehghani-Ghorbi M, Sabaghian T, saberian F. Evaluating the Effect of Metformin in Preventing the Progression from Prediabetes to Type II Diabetes in Iran. J Diabetes Nurs 2024; 12 (4) :2535-2546
URL: http://jdn.zbmu.ac.ir/article-1-652-en.html
URL: http://jdn.zbmu.ac.ir/article-1-652-en.html
Alireza Ebadi 
, Sina Homaee , Soheila Sadeghi , Mahmoud Dehghani-Ghorbi , Tahereh Sabaghian , Farnaz Saberian
, Sina Homaee , Soheila Sadeghi , Mahmoud Dehghani-Ghorbi , Tahereh Sabaghian , Farnaz Saberian
Shahid Beheshti University of Medical Sciences , dr.f.saberian@gmail.com
Abstract: (424 Views)
Introduction: Type II diabetes is a chronic disease with increasing prevalence, imposing substantial costs on patients due to medical care needs. This study aimed to investigate the effect of metformin in preventing the progression from prediabetes to type II diabetes in an Iranian population.
Materials and Methods: This randomized double-blind clinical trial was conducted among individuals with prediabetes enrolled in the Tehran Lipid and Glucose Study. Participants were randomly assigned to one of three groups: (1) the metformin group (metformin along with standard dietary and physical activity advice), (2) the intensive lifestyle group (targeted weight loss >7% and physical activity >150 minutes/week), and (3) the control group (placebo plus standard recommendations). Patients were followed for one year. A significance level of p < 0.05 was considered.
Results: The independent t-test showed a statistically significant difference in mean A total of 181 participants were enrolled, and 89 completed the one-year follow-up (metformin group: 26; intensive group: 31; placebo group: 32). There were no significant differences in baseline anthropometric or demographic variables among the groups. In the intensive group, significant reductions were observed in systolic blood pressure, two-hour plasma glucose, and plasma insulin levels (all p < 0.05). In the metformin group, significant reductions in diastolic blood pressure, cholesterol, and body weight were noted, along with a significant increase in HDL levels—greater than in the other groups (all p < 0.05). None of the interventions led to significant changes in fasting blood glucose, LDL, or triglyceride levels. Interestingly, the greatest weight reduction was observed in the metformin group. At the end of the study, none of the participants in the intensive group progressed to diabetes, indicating the most favorable outcome.
Conclusion: While both metformin and lifestyle modifications were effective in delaying the onset of type II diabetes, lifestyle intervention was significantly more effective. Both interventions performed significantly better than placebo.
Materials and Methods: This randomized double-blind clinical trial was conducted among individuals with prediabetes enrolled in the Tehran Lipid and Glucose Study. Participants were randomly assigned to one of three groups: (1) the metformin group (metformin along with standard dietary and physical activity advice), (2) the intensive lifestyle group (targeted weight loss >7% and physical activity >150 minutes/week), and (3) the control group (placebo plus standard recommendations). Patients were followed for one year. A significance level of p < 0.05 was considered.
Results: The independent t-test showed a statistically significant difference in mean A total of 181 participants were enrolled, and 89 completed the one-year follow-up (metformin group: 26; intensive group: 31; placebo group: 32). There were no significant differences in baseline anthropometric or demographic variables among the groups. In the intensive group, significant reductions were observed in systolic blood pressure, two-hour plasma glucose, and plasma insulin levels (all p < 0.05). In the metformin group, significant reductions in diastolic blood pressure, cholesterol, and body weight were noted, along with a significant increase in HDL levels—greater than in the other groups (all p < 0.05). None of the interventions led to significant changes in fasting blood glucose, LDL, or triglyceride levels. Interestingly, the greatest weight reduction was observed in the metformin group. At the end of the study, none of the participants in the intensive group progressed to diabetes, indicating the most favorable outcome.
Conclusion: While both metformin and lifestyle modifications were effective in delaying the onset of type II diabetes, lifestyle intervention was significantly more effective. Both interventions performed significantly better than placebo.
Type of Study: Research |
Subject:
Nursing care plan for hyper glycemia
Received: 2024/12/2 | Accepted: 2025/03/17 | Published: 2025/03/17
Received: 2024/12/2 | Accepted: 2025/03/17 | Published: 2025/03/17
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |